NASDAQ:AQST Aquestive Therapeutics (AQST) Stock Price, News & Analysis $4.23 +0.06 (+1.44%) Closing price 05/21/2026 04:00 PM EasternExtended Trading$4.25 +0.02 (+0.54%) As of 05/21/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Aquestive Therapeutics Stock (NASDAQ:AQST) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aquestive Therapeutics alerts:Sign Up Key Stats Today's Range$4.09▼$4.2650-Day Range$3.88▼$4.7352-Week Range$2.22▼$7.55Volume1.35 million shsAverage Volume1.71 million shsMarket Capitalization$530.65 millionP/E RatioN/ADividend YieldN/APrice Target$8.80Consensus RatingBuy Company Overview Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms. The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S. Food and Drug Administration for the acute treatment of seizure clusters in patients with epilepsy. In addition to internally developed assets, Aquestive licenses its PharmFilm platform to third parties, supporting products such as Nexafed® (pseudoephedrine) and Vazalore® (aspirin), both of which incorporate abuse‐deterrent or gastrointestinal safety features. Aquestive maintains a robust development pipeline, including Qtrypta™ (sumatriptan) for the acute treatment of migraine, which is in late‐stage regulatory review. The company’s research activities also span novel formulations in pain management, central nervous system disorders and other therapeutic areas where film technology can enhance drug delivery characteristics. Originally founded as MonoSol Rx in 2004, the company rebranded as Aquestive Therapeutics in 2018 to reflect its broader strategic focus. Headquartered in Warren, New Jersey, Aquestive operates facilities for research, development and manufacturing in the United States. Under the leadership of President and Chief Executive Officer Albert J. “Al” Altomari, the company continues to pursue commercial growth and expansion of its PharmFilm platform globally.AI Generated. May Contain Errors. Read More Aquestive Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreAQST MarketRank™: Aquestive Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 522nd out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingBuy Consensus RatingAquestive Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAquestive Therapeutics has a consensus price target of $8.80, representing about 108.0% upside from its current price of $4.23.Amount of Analyst CoverageAquestive Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Aquestive Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aquestive Therapeutics are expected to grow in the coming year, from ($0.43) to ($0.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aquestive Therapeutics is -6.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aquestive Therapeutics is -6.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.38% of the float of Aquestive Therapeutics has been sold short.Short Interest Ratio / Days to CoverAquestive Therapeutics has a short interest ratio ("days to cover") of 12.61, which indicates bearish sentiment.Change versus previous monthShort interest in Aquestive Therapeutics has recently decreased by 0.15%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAquestive Therapeutics does not currently pay a dividend.Dividend GrowthAquestive Therapeutics does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment-0.35 News SentimentAquestive Therapeutics has a news sentiment score of -0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Aquestive Therapeutics this week, compared to 8 articles on an average week.Search Interest17 people have searched for AQST on MarketBeat in the last 30 days. This is an increase of 6% compared to the previous 30 days.MarketBeat Follows7 people have added Aquestive Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Aquestive Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,685,450.00 in company stock.Percentage Held by Insiders6.81% of the stock of Aquestive Therapeutics is held by insiders.Percentage Held by Institutions32.45% of the stock of Aquestive Therapeutics is held by institutions.Read more about Aquestive Therapeutics' insider trading history. Receive AQST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AQST Stock News HeadlinesAquestive Therapeutics (NASDAQ:AQST) CEO Sells $35,422.53 in StockMay 19 at 5:07 AM | insidertrades.comAquestive Therapeutics (NASDAQ:AQST) Trading Down 9.6% - Here's WhyMay 17, 2026 | americanbankingnews.comRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change. | Porter & Company (Ad)The Aquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Are Out And Analysts Have Published New ForecastsMay 16, 2026 | finance.yahoo.comWall Street Zen Upgrades Aquestive Therapeutics (NASDAQ:AQST) to "Hold"May 16, 2026 | americanbankingnews.comAquestive Therapeutics Inc (AQST) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...May 14, 2026 | finance.yahoo.comAquestive Therapeutics Signals Momentum In Earnings CallMay 14, 2026 | tipranks.comAquestive Therapeutics, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 14, 2026 | seekingalpha.comSee More Headlines AQST Stock Analysis - Frequently Asked Questions How have AQST shares performed this year? Aquestive Therapeutics' stock was trading at $6.46 at the start of the year. Since then, AQST shares have decreased by 34.5% and is now trading at $4.23. How were Aquestive Therapeutics' earnings last quarter? Aquestive Therapeutics, Inc. (NASDAQ:AQST) posted its earnings results on Wednesday, May, 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.07. The business earned $14.45 million during the quarter, compared to analysts' expectations of $10.90 million. Read the conference call transcript. When did Aquestive Therapeutics IPO? Aquestive Therapeutics (AQST) raised $68 million in an IPO on Wednesday, July 25th 2018. The company issued 4,500,000 shares at $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers. Who are Aquestive Therapeutics' major shareholders? Top institutional investors of Aquestive Therapeutics include Bank of America Corp DE (1.92%), Janney Montgomery Scott LLC (0.89%), Wasatch Advisors LP (0.72%) and Walleye Capital LLC (0.47%). Insiders that own company stock include Alexander Mark Schobel, Daniel Barber, Lori J Braender, A Ernest Toth Jr, Peter E Boyd, Carl N Kraus, Cassie Jung, Melina Cioffi and Sherry Korczynski. View institutional ownership trends. How do I buy shares of Aquestive Therapeutics? Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aquestive Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aquestive Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and GE Aerospace (GE). Company Calendar Last Earnings5/13/2026Today5/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 AQST's financial health is in the Red zone, according to TradeSmith. AQST has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AQST CIK1398733 Webwww.aquestive.com Phone(908) 941-1900FaxN/AEmployees160Year Founded2004Price Target and Rating Average Price Target for Aquestive Therapeutics$8.80 High Price Target$12.00 Low Price Target$6.00 Potential Upside/Downside+108.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$83.78 million Net Margins-137.08% Pretax Margin-137.08% Return on EquityN/A Return on Assets-49.33% Debt Debt-to-Equity RatioN/A Current Ratio4.10 Quick Ratio3.85 Sales & Book Value Annual Sales$44.54 million Price / Sales11.91 Cash FlowN/A Price / Cash FlowN/A Book Value($0.27) per share Price / Book-15.67Miscellaneous Outstanding Shares125,450,000Free Float116,907,000Market Cap$530.65 million OptionableOptionable Beta1.50 Social Links The 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:AQST) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredI had never heard of this 1888 accountAn investment account dating back to 1888 has quietly delivered average annual returns of 29% over the last 25...The Oxford Club | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquestive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquestive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
